Stocks
Investment Opportunities in Techno Drugs Considering Financial Viability
Techno Drugs Limited’s private company primarily focuses on specialized products, offering a range of products in Oncology, Anesthesia, Birth Control Pills, Injections, and modern technology Implant sticks (for 5-year birth control). The company was registered as a private company in 2009 and converted into a public company in 2019. Additionally providing veterinary and general human medicines.
Their main medicines include:
Birth Control Medicines: Sukhi 3rd Generation oral pill, Provera Injection, Implant Stick 5 years birth control
Anti-cancer Medicines: Hertin, Zolomide, Eposide
Anesthesia Medicines: Lidocaine plus Inj, Vencuron-10 IV Inj
General Human Medicines: Motilex Suspension, Omsec, Romilac, Cefixon Injection.
Veterinary Medicines: Vermic Inj, Dexavet Inj, Rumen plus pow, Vitazinc Sol
Techno Drugs Limited has been advancing in producing and distributing high-quality medicines. The company’s management director, Mehereen Ahmed, holds a PhD in Oncology from Dhaka University, ensuring expertise in the field. The management team and staff work diligently to ensure quality.
Every year, Techno Drugs Limited supplies the highest amount of birth control medicines in opposition to tenders from the Family Planning Directorate of the Bangladesh Government. With 17 depots across the country, they ensure nationwide distribution. The company also has a “24/7 Monitoring Team” at every level to ensure proper monitoring of all company operations.
With listing on the stock market, Techno Drugs Limited anticipates increased production and sales, benefiting investors and stockholders. Their commitment to corporate governance, job creation, business expansion through IPO funds, and regular dividends to investors aims at socio-economic development in the country and enhancing the country’s reputation in the global pharmaceutical market.
Techno Drugs continues to produce life-saving medicines and is progressing as a profitable company. With various specialized products and a wide range of human and veterinary medicines, they aim for further advancement in the future. Currently, the company’s total capital is approximately 94 crores taka with management holding 63% and the management board having 88% of the shares. Techno Drugs believes that with their capable management and dedicated staff, they will achieve more success in the future, making it a secure investment for investors.
Dhaka Stock Market DSE, Bourse on the last working day of the week, 25th July, ended with a hike in Indices and Turnover from the previous working session. This information is known from DSE sources.
497 crore 34 lakh taka shares were traded on this day. 337 crore 97 lakh more tradings were done in DSE today compared to the previous workday, July 24th, Shares worth Tk 159 crores 37 lakh shares were traded last time, Wednesday.
The benchmark DSEX increased 62.81 points or 5,413 The Shariah-based index DSES added 13.81 points or 1,183 and the blue-chip index DS30 gained by 24.25 points or 1,932.
Of the issues traded, 286 advanced, 66 declined and 40 remained unchanged.
Techno Drugs Limited ranked top gainer on DSE, the share price increased by Tk 3.80 paisa or 9.87 percent. On this day, the share was last traded at Tk 42.30 paisa.
Rangpur Foundry Limited ranked top loser on the DSE, the share price dropped by Tk 5.40 paisa or 2.98 percent. On this day, the share was last traded at Tk 175.70 paisa.
DSE topped on trade is Square Pharmaceuticals PLC 35 crore 9 lakh takas of company shares have been traded.
A total of 28 companies’ shares were traded in the Block on Dhaka Stock Exchange. A total of 82 lakh 94 thousand 29 shares of the companies were traded. The financial value of which is 21 crore 92 lakh taka
One of the listed companies, Eastland Insurance Company Limited discloses its financial reports for the second quarter, (April – June 24).
The company’s earnings per share (EPS) Tk 0.27 paisa in Q2 of the current financial year (April – June 24). EPS was Tk. 0.41 for January-June 2024 as against Tk. 1.47 for the same period last year. EPS was Tk 0.80 paisa during the same period last year. NAV per share was Tk. 20.85 as of June 30, 2024.
One of the listed companies, Shahjalal Islami Bank PLC discloses its financial reports for the second quarter, (April – June 24).
The company’s Consolidated earnings per share (EPS) Tk 1.50 paisa in Q2 of the current financial year (April – June 24). Consolidated EPS was Tk. 1.50 for January-June 2024 as against Tk. 1.47 for the same period last year. EPS was Tk 0.80 paisa during the same period last year. Consolidated NAV per share was Tk. 20.85 as of June 30, 2024.
